您的位置: 首页 > 农业专利 > 详情页

Cannabidiol derivatives as inhibitors of the hif prolyl hydroxylases activity
专利权人:
Emerald Health Pharmaceuticals; Inc.
发明人:
Muñoz Blanco, Eduardo,Navarrete Rueda, Carmen María,Cruz Teno, Cristina,Bellido Cabello De Alba, María Luz
申请号:
AU2017406103
公开号:
AU2017406103A1
申请日:
2017.03.29
申请国别(地区):
AU
年份:
2019
代理人:
摘要:
Cannabidiol quinol derivatives of Formula (I) and compositions comprising the same for use in the treatment of conditions that benefit from the inhibition of the HIF prolyl hydroxylases (PHDs) activity are described. Said cannabidiol quinol derivatives of Formula (I), and compositions comprising the same, show thus capacity to inhibit PHD activities and, as a result, stabilize the HIF- 1α and HIF-2α levels, activate the HIF pathway in different cell types, induce angiogenesis in human endothelial vascular cell, regulate HIF-dependent gene expression in different cell types 10 and induce collagen contraction. Said cannabidiol quinol derivatives of Fomula (I) are useful in the treatment of conditions that benefit from the inhibition of the HIF prolyl hydroxylases (PHDs) activity such as stroke, traumatic injuries anemia, myocardial ischaemia–reperfusion injury, acute lung injury, infectious diseases, diabetic and chronic wounds, organ transplantation, acute kidney injury or arterial diseases.
来源网站:
中国工程科技知识中心
来源网址:
http://www.ckcest.cn/home/

意 见 箱

匿名:登录

个人用户登录

找回密码

第三方账号登录

忘记密码

个人用户注册

必须为有效邮箱
6~16位数字与字母组合
6~16位数字与字母组合
请输入正确的手机号码

信息补充